BioWorld

Feb. 9, 2009

Idenix, GSK Team Up in $450M HIV Deal

Idenix Pharmaceuticals Inc. has granted London-based GlaxoSmithKline plc worldwide rights to IDX899, a potential treatment for HIV/AIDS, in a deal that could bring in a potential $450 million for the U.S-based biotech. (BioWorld Today) Read More

Biogen Hits Earnings Estimates, Though Tysabri Sales Fall Short

FDA Accepts Roxro's NDA for Intranasal Non-Narcotic Painkiller

Dems Pledge Health Reform Despite Loss of Daschle

Avigen's Board Rejects BVF Bid; Urges Shareholders to Pass

GTC's ATryn Wins One OK, Loses on Broader Indication

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...